UNLABELLED: p-(131)I-iodo-L-phenylalanine ((131)I-IPA) is a tumor-specific amino acid derivative that demonstrated antiproliferative and tumoricidal effects on experimental gliomas. This study tested the efficacy of (131)I-IPA combined with external beam photon radiotherapy as a new therapeutic approach against gliomas. METHODS: Glioma cells derived from the rat F98 glioma or human Tx3868 or A1207 glioblastoma cell lines were stereotactically inoculated into the brains of Fischer 344 rats or RNU rats. Tumor formation was verified radiologically. On day 8, groups of glioma-bearing rats of each tumor model underwent whole-brain radiotherapy with 8 Gy, an intravenous administration of (131)I-IPA (30 MBq), or combined treatment, aiming for a total of 12 rats per group. Another 12 animals were treated with physiologic saline and served as control. RESULTS: Control rats had a combined median survival (+/-SD) of 21 +/- 6 d. All revealed metabolically and histologically large tumor masses. Efficacy of radiotherapy alone or a monotherapy with 30 MBq of (131)I-IPA was statistically insignificant on the syngeneic Fischer-F98 model (P >or= 0.45 and P = 0.10, respectively). In contrast, a subset of long-term survivors (>120 d) was observed in RNU rats bearing Tx3868 and A1207 glioblastoma xenografts (18%-25% and 35%-45% for radiotherapy and (131)I-IPA, respectively). Combined (131)I-IPA and radiotherapy treatment significantly prolonged median survival for the syngeneic Fischer-F98 glioma model (P < 0.01) and human glioblastoma-bearing RNU rats alike (P < 0.05). On day 120 after monotherapy with (131)I-IPA, 45% of the RNU rats were still alive, but after 8 Gy of photon radiotherapy only 18%-25% of the RNU and none of the Fischer rats survived. In comparison, 55%-75% survival rates were registered after combined treatment on day 120 for all animal models. CONCLUSION: These data convincingly demonstrated that systemic radionuclide therapy with (131)I-IPA combined with external photon radiotherapy is a safe and highly effective treatment for experimental gliomas, which may merit a clinical trial to ascertain its potential in patients with gliomas. Because only a low (131)I-IPA activity and low radiotherapy doses were applied, further optimizations including higher radiation doses and conventional fractionated radiotherapy are warranted.
UNLABELLED: p-(131)I-iodo-L-phenylalanine ((131)I-IPA) is a tumor-specific amino acid derivative that demonstrated antiproliferative and tumoricidal effects on experimental gliomas. This study tested the efficacy of (131)I-IPA combined with external beam photon radiotherapy as a new therapeutic approach against gliomas. METHODS:Glioma cells derived from the rat F98 glioma or human Tx3868 or A1207 glioblastoma cell lines were stereotactically inoculated into the brains of Fischer 344 rats or RNUrats. Tumor formation was verified radiologically. On day 8, groups of glioma-bearing rats of each tumor model underwent whole-brain radiotherapy with 8 Gy, an intravenous administration of (131)I-IPA (30 MBq), or combined treatment, aiming for a total of 12 rats per group. Another 12 animals were treated with physiologic saline and served as control. RESULTS: Control rats had a combined median survival (+/-SD) of 21 +/- 6 d. All revealed metabolically and histologically large tumor masses. Efficacy of radiotherapy alone or a monotherapy with 30 MBq of (131)I-IPA was statistically insignificant on the syngeneic Fischer-F98 model (P >or= 0.45 and P = 0.10, respectively). In contrast, a subset of long-term survivors (>120 d) was observed in RNUrats bearing Tx3868 and A1207 glioblastoma xenografts (18%-25% and 35%-45% for radiotherapy and (131)I-IPA, respectively). Combined (131)I-IPA and radiotherapy treatment significantly prolonged median survival for the syngeneic Fischer-F98 glioma model (P < 0.01) and humanglioblastoma-bearing RNUrats alike (P < 0.05). On day 120 after monotherapy with (131)I-IPA, 45% of the RNUrats were still alive, but after 8 Gy of photon radiotherapy only 18%-25% of the RNU and none of the Fischer rats survived. In comparison, 55%-75% survival rates were registered after combined treatment on day 120 for all animal models. CONCLUSION: These data convincingly demonstrated that systemic radionuclide therapy with (131)I-IPA combined with external photon radiotherapy is a safe and highly effective treatment for experimental gliomas, which may merit a clinical trial to ascertain its potential in patients with gliomas. Because only a low (131)I-IPA activity and low radiotherapy doses were applied, further optimizations including higher radiation doses and conventional fractionated radiotherapy are warranted.
Authors: Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Andrea Schaefer; Georgios Farmakis; Aleksandar Grgic; Jean R Moringlane; Wolf-Ingo Steudel; Carl-Martin Kirsch; Samuel Samnick Journal: Eur J Nucl Med Mol Imaging Date: 2010-07-30 Impact factor: 9.236
Authors: Richard P Baum; Andreas Kluge; Franz Josef Gildehaus; Marcus Bronzel; Karl Schmidt; Christiane Schuchardt; Stephan Senftleben; Samuel Samnick Journal: Nucl Med Mol Imaging Date: 2011-11-16
Authors: Michael C Kreissl; Heribert Hänscheid; Mario Löhr; Frederik A Verburg; Markus Schiller; Michael Lassmann; Christoph Reiners; Samuel S Samnick; Andreas K Buck; Michael Flentje; Reinhart A Sweeney Journal: Radiat Oncol Date: 2012-06-21 Impact factor: 3.481